Second City Outcomes Research, Oak Park, IL 60302, USA.
Value Health. 2012 Mar-Apr;15(2):305-11. doi: 10.1016/j.jval.2011.11.029. Epub 2012 Feb 2.
OBJECTIVE: Although utility-based algorithms have been developed for the Functional Assessment of Cancer Therapy (FACT), their properties are not well known compared with those of generic utility measures such as the EQ-5D. Our objective was to compare EQ-5D and FACT preference-based scores in cancer patients. METHODS: A retrospective analysis was conducted on cross-sectional data collected from 472 cancer patients who completed both FACT-General and the EQ-5D. Preference-based scores were calculated by using published scoring functions for the EQ-5D (Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108; Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20) and FACT (Dobrez D, Cella D, Pickard AS, et al. Estimation of patient preference-based utility weights from the Functional Assessment of Cancer Therapy-General. Value Health 2007;10:266-72; Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics 2005;23:1143-53; Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health 2009;12:371-6). Scores were compared on the basis of clinical severity by using Eastern Cooperative Oncology Group performance status ratings by physicians and patients. Relative efficiency of each scoring function was examined by using ratios of F statistics. RESULTS: Mean scores for the overall cohort were lowest when using Kind and Macran's FACT UK societal algorithm (0.55, SD 0.09) and highest when using Dobrez et al.'s FACT US patient algorithm (0.83, SD 0.08). Mean difference scores associated with clinical severity, when extrapolated to quality-adjusted life-years (QALYs), had a range of 0.18 QALYs gained using FACT (Kind and Macran) to 0.45 QALYs gained using the EQ-5D (Dolan). However, relative efficiencies suggested that FACT (Kind and Macran) scores may provide greater statistical power to detect significant differences based on clinical severity. CONCLUSIONS: We found important differences in utilities scores estimated by each algorithm, with FACT-based algorithms tending to underestimate the QALY benefit compared with algorithms based on the EQ-5D. These differences highlight some of the challenges in using disease-specific preference-based measures for decision making despite potentially more relevant disease-specific content.
目的:虽然已经为癌症疗法的功能性评估(FACT)开发了基于效用的算法,但与通用效用测量(如 EQ-5D)相比,它们的特性尚不清楚。我们的目的是比较癌症患者的 EQ-5D 和 FACT 偏好得分。
方法:对来自 472 名同时完成 FACT-General 和 EQ-5D 的癌症患者的横断面数据进行回顾性分析。使用发表的 EQ-5D 评分函数(Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108; Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20)和 FACT(Dobrez D, Cella D, Pickard AS, et al. Estimation of patient preference-based utility weights from the Functional Assessment of Cancer Therapy-General. Value Health 2007;10:266-72; Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics 2005;23:1143-53; Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health 2009;12:371-6)计算偏好得分。根据医生和患者的东部合作肿瘤学组表现状态评分,基于临床严重程度对评分进行比较。通过 F 统计量的比值检查每个评分函数的相对效率。
结果:总体队列的平均得分最低的是 Kind 和 Macran 的 FACT UK 社会算法(0.55,SD 0.09),最高的是 Dobrez 等人的 FACT US 患者算法(0.83,SD 0.08)。当外推至质量调整生命年(QALY)时,与临床严重程度相关的平均差异评分范围为 0.18 QALY 获益(FACT(Kind 和 Macran))至 0.45 QALY 获益(Dolan 的 EQ-5D)。然而,相对效率表明,FACT(Kind 和 Macran)评分可能基于临床严重程度提供更大的统计能力来检测显著差异。
结论:我们发现每个算法估计的效用得分存在重要差异,基于 FACT 的算法与基于 EQ-5D 的算法相比,往往低估了 QALY 获益。这些差异突出了尽管具有潜在更相关的疾病特异性内容,但使用特定于疾病的偏好测量方法进行决策时面临的一些挑战。
Value Health. 2012-2-2
JAMA Otolaryngol Head Neck Surg. 2015-8
Drug Alcohol Depend. 2008-1-1
Value Health. 2010-4-15
Pharmacoecon Open. 2021-9
Prostate Cancer Prostatic Dis. 2021-9